Toleranzia develops drugs that utilize the immune system’s own intrinsic power to treat autoimmune orphan diseases. The drugs target the cause of the disease and can cure or greatly alleviate the disease and not only reduce the symptoms as currently available treatments do.
The company’s drug candidate, TOL2, is being developed for the treatment of the autoimmune neuromuscular disease myasthenia gravis, an orphan disease, which has a major unmet medical need and a large market potential.
News & press releases
4 October - 2019